Infliximab and ciclosporin appear to be equally effective in treating steroid-resistant acute, severe ulcerative colitis, according to results of a trial. In terms of quality-adjusted survival, there was no significant difference between infliximab and ciclosporin (mean adjusted difference 7.9, 95 percent confidence interval [CI], -22.0 to 37.8; p=0.603).
[ Lancet Gastroenterol Hepatol 2016;doi:10.1016/S2468-1253(16)30003-6] Frequency of colectomy was also similar between groups (41 vs 48 percent in the infliximab and ciclosporin groups, respectively; odds ratio [OR], 1.350, 95 percent CI, 0.832 to 2.188; p=0.223), as was mean time to colectomy (811 vs 744 days in the infliximab and ciclosporin groups, respectively; hazard ratio [HR], 1.234, 95 percent CI, 0.862 to 1.768; p=0.251). The number of serious adverse reactions and events was also similar between the infliximab and ciclosporin…
